Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572388 | 1.00 | ALDH1A1 (0.68) | ALDH1A1KDM4EGFERL3MBTL1MEN1 | |
| SCHEMBL11489064 | 0.90 | ALDH1A1 (0.56) | ALDH1A1KDM4EGFERL3MBTL1MEN1 | |
| SCHEMBL11465020 | 0.84 | LMNA (0.61) | ALDH1A1KDM4EGFERL3MBTL1LMNA | |
| SCHEMBL8267685 | 0.83 | ALDH1A1 (0.69) | ALDH1A1KDM4EGFERL3MBTL1KMT2A | |
| SCHEMBL3228765 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KDM4EGFERL3MBTL1MEN1 | |
| SCHEMBL15220059 | 0.83 | ACHE (0.54) | ALDH1A1 | |
| SCHEMBL14452546 | 0.83 | POLB (0.51) | ALDH1A1KDM4EGFERL3MBTL1MEN1 | |
| SCHEMBL16233184 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ALMNAPOLB | |
| Hydrochloric Acid SCHEMBL11194452 | 0.83 | LMNA (0.64) | ALDH1A1L3MBTL1KMT2ALMNANPC1 | |
| Hydrochloric Acid SCHEMBL11176717 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KDM4EGFERL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-2900223-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9359346-B2 | Benzamide derivative and use thereof | VIVOZON, INC. (KR) | 2016-06-07 | — | — | US | disclosed |
| US-9226922-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | VIVOZON, INC. (KR) | 2014-11-13 | — | — | US | disclosed |
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
| US-7629468-B2 | Neuroprotectants, analgesics or anticonvulsants | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-08 | — | — | US | disclosed |
| EP-1332133-B1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| US-7220884-B2 | Hydroaminomethylation of olefins | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| CN-1918110-A | Hydroaminomethylation of olefins | UNION CARBIDE CHEM PLASTIC (US) | 2007-02-21 | — | — | CN | disclosed |
| EP-1713757-A2 | HYDROAMINOMETHYLATION OF OLEFINS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050215825-A1 | Hydroaminomethylation of olefins | UNION CARBIDE CORPORATION | 2005-09-29 | — | — | US | disclosed |
| WO-2005077884-A2 | HYDROAMINOMETHYLATION OF OLEFINS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| EP-1265844-A1 | METHOD FOR PRODUCING AMINES BY THE HYDROAMINOMETHYLATION OF OLEFINS IN THE PRESENCE OF IONIC LIQUIDS | Bayer Aktiengesellschaft (DE) | 2002-12-18 | — | — | EP | disclosed |
| US-20010047097-A1 | Process for the preparation of arylethylamines by amination of arylolefins | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 2001-11-29 | — | — | US | disclosed |
| EP-1157983-A1 | Process for the preparation of arylethylamines via the amination of arylolefins | Aventis Research & Technologies GmbH & Co KG (DE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001064621-A1 | METHOD FOR PRODUCING AMINES BY THE HYDROAMINOMETHYLATION OF OLEFINS IN THE PRESENCE OF IONIC LIQUIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215825-A1 | Hydroaminomethylation of olefins | HRH2, HRH4, HRH1 | ALDH1A1 1249/4885KDM4E 3389/4885GFER 1504/4885 |
| US-20140336378-A1 | NOVEL BENZAMIDE DERIVATIVE AND USE THEREOF | TRPV1, TRPA1, TRPV5 | ALDH1A1 129/4885KDM4E 1505/4885GFER 2607/4885 |
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | ALDH1A1 670/4885KDM4E 2007/4885GFER 4113/4885 |
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | ALDH1A1 172/4885KDM4E 3753/4885GFER 1660/4885 |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | ALDH1A1 358/4885KDM4E 2166/4885GFER 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.